-
3 days ago | 
ophthalmologytimes.com | David S. Boyer |Sydney M Crago
David S. Boyer, MD, discusses a new approach to treating diabetic retinopathy and macular degeneration using suprachoroidal space injections. This innovative technique offers significant advantages over traditional intravitreal injections by providing a less invasive, office-based procedure with dramatically reduced inflammatory risks. Note: The following conversation has been lightly edited for clarity.
-
5 days ago | 
modernretina.com | David S. Boyer |Sydney M Crago
David S. Boyer, MD, discusses a new approach to treating diabetic retinopathy and macular degeneration using suprachoroidal space injections. This innovative technique offers significant advantages over traditional intravitreal injections by providing a less invasive, office-based procedure with dramatically reduced inflammatory risks. The study examined 3 dosing regimens (2.5e-11, 5e-11, and 1e-12) across different patient groups with diabetic retinopathy.
-
6 days ago | 
ophthalmologytimes.com | Rachel A. Downes |Sydney M Crago
At the 2025 Retina World Congress meeting, held in Fort Lauderdale, Florida from May 8-11, 2025, Rachel Downes, MD, a Vitreoretinal Surgery Fellow at Cleveland Clinic Cole Eye Institute, presented data from the GATHER1 and GATHER2 clinical trials. Ophthalmology Times connected with Downes to learn more about this presentation and the key takeaways. Note: This Q&A has been lightly edited for clarity.
-
1 week ago | 
modernretina.com | J. Arevalo |Sydney M Crago
Johns Hopkins researcher J. Fernando Arevalo, MD, PhD, FACS, FASRS, presents ELEVATUM, a pioneering multicountry study examining faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities. The research focused on 124 patients across 40 centers in the United States, targeting individuals aged 18 and older with type 1 or type 2 diabetes.
-
1 week ago | 
ophthalmologytimes.com | Sydney M Crago |Baruch D. Kuppermann
At the 2025 Retina World Congress, Opthalmology Times spoke with Baruch D. Kuppermann, MD, PhD, about this international meeting and how it showcases diverse perspectives from global retina specialists, focusing equally on surgical and medical retina innovations. He noted that the conference highlights emerging treatment practices and innovations like extended interval therapies, drug delivery systems, and viral vector gene therapies. Note: This conversation has been lightly edited for clarity.
-
1 week ago | 
ophthalmologytimes.com | Sharon Fekrat |Sydney M Crago
Sharon Fekrat, MD, FACS, FASRS, a professor of ophthalmology and neurology at Duke University School of Medicine, highlights the critical importance of networking and collaboration in the medical field, particularly in ophthalmology. She emphasizes that international meetings are far more than just formal lectures and panels, serving as crucial platforms for building global connections and sparking innovative ideas. Note: The following conversation has been lightly edited for clarity.
-
1 week ago | 
ophthalmologytimes.com | Dilraj S. Grewal |Sydney M Crago |Kassi Filkins
Dilraj S. Grewal, MD, FASRS, an associate professor of ophthalmology at Duke Eye Center, spoke with Ophthalmology Times at the 2025 Retina World Congress meeting held in Fort Lauderdale, Florida. At this meeting, Grewal gave a presentation entitled, "New therapeutics for non-infectious uveitis in 2025," which provided an in-depth overview of the current state of research and treatment innovations. Note: This conversation has been lightly edited for clarity.
-
1 week ago | 
ophthalmologytimes.com | Priya S. Vakharia |Sydney M Crago |Kassi Filkins
Priya S. Vakharia, MD, a retina specialist at Retina Vitreous Associates of Florida in Tampa Bay, presented findings from the ARCHER trial investigating geographic atrophy (GA) treatment for dry age-related macular degeneration (AMD) during the 2025 Retina World Congress annual meeting. Note: The following conversation has been lightly edited for clarity. Ophthalmology Times: You presented on the ARCHER trial here at Retina World Congress. Can you give us a few highlights from this presentation?
-
1 week ago | 
ophthalmologytimes.com | Sydney M Crago |Sunir J. Garg |Kassi Filkins
Sunir Garg, MD, a professor of ophthalmology at Wills Eye Hospital and partner with Mid-Atlantic Retina, discussed with Ophthalmology Times one significant challenge in ophthalmological procedures: patient discomfort during intravitreal injections caused by povidone iodine. Note: The following conversation has been lightly edited for clarity. Ophthalmology Times: Can you share more about the the challenges behind current anti-sepsis options for intravitreal injections?
-
1 week ago | 
modernretina.com | David Tanzer |Sydney M Crago
May 29, 2025By Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative patient care strategies. David Tanzer, MD, Lexitas Pharma Services' CMO, met up with Modern Retina® to chat during the 2025 Retina World Congress annual meeting.
